Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I/II open-label study of RG002 in HPV16/18-associated cervical intraepithelial neoplasia grade 2/3
CTR20251020Phase 2Active
- Sponsor
- RinuaGene Biotechnology
- Start
- Mar 2025
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of RG002 in cervical intraepithelial neoplasia (CIN), sponsored by RinuaGene Biotechnology. Started Mar 2025; status: active.
02
Drugs
RG002
03
Conditions
cervical intraepithelial neoplasia (CIN)
Beyond the preview
Go deeper on CTR20251020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20251020.